First Light Asset Management LLC increased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 27.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 337,912 shares of the company’s stock after buying an additional 72,815 shares during the period. TransMedics Group comprises about 2.3% of First Light Asset Management LLC’s holdings, making the stock its 16th largest position. First Light Asset Management LLC owned about 1.04% of TransMedics Group worth $25,590,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Belpointe Asset Management LLC increased its stake in shares of TransMedics Group by 51.6% during the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after purchasing an additional 190 shares in the last quarter. Dark Forest Capital Management LP acquired a new stake in TransMedics Group during the 1st quarter valued at approximately $51,000. Tucker Asset Management LLC bought a new position in TransMedics Group during the 1st quarter valued at $62,000. Royal Bank of Canada grew its stake in TransMedics Group by 643.0% in the third quarter. Royal Bank of Canada now owns 1,122 shares of the company’s stock worth $46,000 after purchasing an additional 971 shares in the last quarter. Finally, Lagoda Investment Management L.P. bought a new position in TransMedics Group during the first quarter worth $136,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other TransMedics Group news, CEO Waleed H. Hassanein sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $82.51, for a total value of $618,825.00. Following the transaction, the chief executive officer now owns 544,191 shares in the company, valued at approximately $44,901,199.41. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Waleed H. Hassanein sold 7,500 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $82.51, for a total value of $618,825.00. Following the transaction, the chief executive officer now owns 544,191 shares in the company, valued at $44,901,199.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tamer I. Khayal sold 2,974 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $90.05, for a total value of $267,808.70. Following the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at approximately $1,294,468.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,182 shares of company stock worth $2,753,520. 6.70% of the stock is owned by company insiders.
Analysts Set New Price Targets
TransMedics Group Trading Down 2.3 %
TransMedics Group stock traded down $1.35 during midday trading on Tuesday, reaching $58.18. The stock had a trading volume of 241,166 shares, compared to its average volume of 582,536. The firm’s fifty day simple moving average is $76.09 and its two-hundred day simple moving average is $76.40. The company has a debt-to-equity ratio of 3.48, a current ratio of 20.70 and a quick ratio of 19.74. TransMedics Group, Inc. has a twelve month low of $38.86 and a twelve month high of $99.63. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -104.44 and a beta of 1.52.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.12. TransMedics Group had a negative return on equity of 9.98% and a negative net margin of 11.77%. The firm had revenue of $42.46 million during the quarter, compared to the consensus estimate of $42.42 million. During the same period in the prior year, the business earned ($0.41) EPS. The business’s revenue for the quarter was up 136.9% on a year-over-year basis. Equities analysts anticipate that TransMedics Group, Inc. will post -0.51 EPS for the current fiscal year.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Five stocks we like better than TransMedics Group
- Crypto vs Stocks: How to Choose Your Investments
- Ray Dalio’s Move into 3 Stocks, All Betting on One Thing
- What is Put Option Volume?
- Airbnb Joins the S&P 500, Time to Buy In?
- Technology Stocks Explained: Here’s What to Know About Tech
- Does Dell Technologies Blowout Quarter Mean a New Demand Cycle?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.